Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study

Fig. 2

The PFS of different groups. A The PFS between CG and PG. B The PFS between four subgroups in CG. C Tumor response rates between AIC and PG. D The PFS between four subgroups in CG. PG, Personalized group; CG, Chemotherapy group; C, chemotherapy alone subgroup in CG; AC, anti-angiogenesis plus chemotherapy subgroup in CG; IC, immune checkpoint inhibitors plus chemotherapy subgroup in CG; AIC, a combination of immune checkpoint inhibitors, anti-angiogenesis and chemotherapy subgroup in CG. ORR, objective response rate; DCR, disease control rate

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us